ARV-825

Research use only, not for human use.

ARV-825 is a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 via the proteasome.

ARV-825 is a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 via the proteasome; shows more significant and longer lasting c-MYC suppression than small molecule inhibitors (JQ1, OTX015); leads to a superior effect on BL cells proliferation suppression.Breast Cancer,Preclinical

ARV 825;ARV825

Chromatin/Epigenetic

Bromodomain

Bromodomain

Cancer

——

1818885-28-7

923.43

C46H47ClN8O9S

>98% (HPLC)

10 mM in DMSO

O=C(NC1=CC=C(OCCOCCOCCOCCNC2=CC=CC(C(N3C(CC4)C(NC4=O)=O)=O)=C2C3=O)C=C1)C[C@H]5C6=NN=C(C)N6C7=C(C(C)=C(C)S7)C(C8=CC=C(Cl)C=C8)=N5

2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethoxy)phenyl)acetamide

(-20℃)

With Ice Pack

≥ 2 years